Team
In2Cell was founded on more than a decade of hands-on cancer research. The platform is being built by people who have studied, at first hand, how tumours respond to drugs and how they resist them.
Cancer biologist with eight years in drug-resistance research and long-read sequencing, now building POLEX end to end. Read full bio →
We are a small team, growing deliberately. Key commercial and clinical hires are planned as we move through our first patient-sample studies.